#insulin-pricing

#insulin-pricing

The FTC is suing major pharmacy benefit managers for illegal rebate practices that have dramatically increased insulin prices paid by consumers.

The FTC is taking action against major pharmacy benefit managers for inflating insulin prices and harming consumers.

The FTC alleges that pharmacy benefit managers inflate insulin prices through rebate programs, harming patients financially.